^
CANCER:

Oligodendroglioma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
temozolomide
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
bevacizumab
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
carmustine
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
lomustine
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
temozolomide
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
PCV
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
cisplatin
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
carboplatin
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
etoposide IV
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
bevacizumab
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
carmustine
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
lomustine
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
PCV
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
cisplatin
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
carboplatin
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
etoposide IV
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E
Oligodendroglioma
vemurafenib + cobimetinib
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E
Oligodendroglioma
trametinib + dabrafenib
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion
Oligodendroglioma
entrectinib
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion
Oligodendroglioma
entrectinib
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion
Oligodendroglioma
entrectinib
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion
Oligodendroglioma
larotrectinib
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion
Oligodendroglioma
larotrectinib
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion
Oligodendroglioma
larotrectinib
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E
Oligodendroglioma
vemurafenib + cobimetinib
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E
Oligodendroglioma
trametinib + dabrafenib
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion
Oligodendroglioma
entrectinib
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion
Oligodendroglioma
entrectinib
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion
Oligodendroglioma
entrectinib
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion
Oligodendroglioma
larotrectinib
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion
Oligodendroglioma
larotrectinib
Sensitive
:
A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion
Oligodendroglioma
larotrectinib
Sensitive
:
A2